Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : PRESIDENT GEORGE W. BUSH -- Ignore unavailable to you. Want to Upgrade?

To: Thomas A Watson who wrote (173989)	8/23/2001 11:23:15 PM
From: ColtonGang	Respond to of 769667

BUSH MUST RECONSIDER......Stem Cell Research Faces FDA Hurdle With Mouse Cell Base, Tough Rules Apply By Justin Gillis and Ceci Connolly Washington Post Staff Writers Friday, August 24, 2001; Page A1 Most or all of the human embryonic stem cell colonies approved for research funding under a new Bush administration policy have been mixed in the laboratory with mouse cells, which may create substantial hurdles for scientists trying to turn the colonies into treatments for Parkinson's disease, spinal-cord injuries and other ailments. The cell colonies, or "lines," were created for early-stage research with no thought that they would become the only embryonic cells eligible for federal money. But that is the status President Bush conferred on them in his first prime-time address to the nation on Aug. 9. The standard technique for creating human embryonic stem cell lines has been to extract cells from inside a microscopic embryo, then grow them atop embryonic mouse cells, known as "feeder" cells. The latter excrete some unknown nutritional or growth factor that helps the human cells stay healthy. Because they have been in close contact with mouse cells, the human cells pose a small but real risk of transferring potentially deadly animal viruses to people. Because of that, under guidelines the Food and Drug Administration has been developing for several years, it would be difficult, though not impossible, to use the cells in human clinical tests.